Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671868 | 0.87 | HIF1A (0.37) | — | |
| SCHEMBL5908716 | 0.86 | SPHK2 (0.40) | CYP3A4IDO1APPSPHK2SPHK1 | |
| SCHEMBL96078 | 0.83 | SPHK2 (0.48) | CYP3A4SPHK2SPHK1SIGMAR1 | |
| SCHEMBL10012084 | 0.80 | HRH3 (0.41) | — | |
| SCHEMBL1932991 | 0.77 | CYP3A4 (0.42) | CYP3A4IDO1APPCYP1A2CYP2D6 | |
| SCHEMBL910882 | 0.76 | THRB (0.47) | — | |
| SCHEMBL896217 | 0.76 | TAAR1 (0.50) | IDO1 | |
| SCHEMBL1528689 | 0.76 | GFER (0.59) | CYP3A4 | |
| SCHEMBL21176946 | 0.76 | CA2 (0.52) | — | |
| SCHEMBL2320498 | 0.76 | CHKA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018010476-A1 | GLYCOPEPTIDES BASED DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2018-01-18 | — | — | WO | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101068810-B | Carbostyril compound | OTSUKA PHARMA CO LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-0796618-B1 | Treatment and prophylaxis of pancreatitis | SANKYO CO (JP) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5968960-A | ANTIISCHEMIC AGENTS AND HYPOTENSIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-19 | — | — | US | disclosed |
| US-5804590-A | ADMINISTERING DERIVATIVES OF THIAZOLIDINE; ANTI-DIABETIC AGENTS. | SANKYO COMPANY, LIMITED (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5753681-A | INSULIN SENSITIZERS | SANKYO COMPANY, LIMITED (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0783888-A1 | Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis | SANKYO COMPANY LIMITED (JP) | 1997-07-16 | — | — | EP | disclosed |
| EP-0126635-B1 | NOVEL OXINDOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4694017-A | 2-amido 3(oxindol-3-yl)propionic acids having antiulcer activity | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-15 | — | — | US | disclosed |
| EP-0126635-A2 | Novel oxindole derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | CYP3A4 3412/4885IDO1 2039/4885APP 3826/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | CYP3A4 953/4885IDO1 2948/4885APP 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.